Analysis of the predictive value of 6 analytes in 76 samples drawn before the initiation of treatment of GVHD in patients in cohort 2
| . | Area under ROC curve, P value, OR (95% CI), per log increase in analyte . | ||
|---|---|---|---|
| . | Peak grade 2b-4 (n = 28) vs grade 2a (n = 48) . | Peak grade 3-4 (n = 8) vs grade 2 (n = 68) . | NRM at 1 y (n = 11) vs not NRM . |
| HGF | |||
| AUC | 0.58 | 0.61 | 0.73 |
| P | .23 | .40 | .12 |
| OR (95% CI) | 1.9 (0.6-5.8) | 2.0 (0.4-9.0) | 3.0 (0.8-11) |
| IL6 | |||
| AUC | 0.69 | 0.83 | 0.80 |
| P | .007 | .009 | .003 |
| OR (95% CI) | 3.2 (1.3-7.8) | 4.7 (1.4-16) | 4.9 (1.6-15) |
| ST2 | |||
| AUC | 0.64 | 0.78 | 0.73 |
| P | .04 | .01 | .003 |
| OR (95% CI) | 5.5 (1.0-31) | 26.3 (1.9-367) | 29.2 (2.6-335) |
| TIM3 | |||
| AUC | 0.64 | 0.81 | 0.82 |
| P | .04 | .004 | .0007 |
| OR (95% CI) | 5.0 (1.0-24) | 46.1 (2.3-926) | 59.8 (3.8-946) |
| TNFα | |||
| AUC | 0.52 | 0.61 | 0.69 |
| P | .85 | .38 | .07 |
| OR (95% CI) | 1.2 (0.2-9.3) | 4.1 (0.2-96) | 13.7 (0.7-260) |
| sTNFR1 | |||
| AUC | 0.60 | 0.67 | 0.88 |
| P | .26 | .21 | ≤.0001 |
| OR (95% CI) | 3.4 (0.4-30) | 8.3 (0.3-235) | 999+ (19-999+) |
| Best model by forward selection | IL6 | IL6, TIM3, sTNFR1 | ST2, sTNFR1 |
| AUC | .69 | .88 | .90 |
| P | .007 | .001 | <.0001 |
| OR (95% CI) | 3.2 (1.3-7.8) | 6.8 (1.3-35), 519 (3.6-999+), 0.0 (0.0-1.5), respectively | 17.2 (1.3-232), 999+ (13.3-1000+), respectively |
| . | Area under ROC curve, P value, OR (95% CI), per log increase in analyte . | ||
|---|---|---|---|
| . | Peak grade 2b-4 (n = 28) vs grade 2a (n = 48) . | Peak grade 3-4 (n = 8) vs grade 2 (n = 68) . | NRM at 1 y (n = 11) vs not NRM . |
| HGF | |||
| AUC | 0.58 | 0.61 | 0.73 |
| P | .23 | .40 | .12 |
| OR (95% CI) | 1.9 (0.6-5.8) | 2.0 (0.4-9.0) | 3.0 (0.8-11) |
| IL6 | |||
| AUC | 0.69 | 0.83 | 0.80 |
| P | .007 | .009 | .003 |
| OR (95% CI) | 3.2 (1.3-7.8) | 4.7 (1.4-16) | 4.9 (1.6-15) |
| ST2 | |||
| AUC | 0.64 | 0.78 | 0.73 |
| P | .04 | .01 | .003 |
| OR (95% CI) | 5.5 (1.0-31) | 26.3 (1.9-367) | 29.2 (2.6-335) |
| TIM3 | |||
| AUC | 0.64 | 0.81 | 0.82 |
| P | .04 | .004 | .0007 |
| OR (95% CI) | 5.0 (1.0-24) | 46.1 (2.3-926) | 59.8 (3.8-946) |
| TNFα | |||
| AUC | 0.52 | 0.61 | 0.69 |
| P | .85 | .38 | .07 |
| OR (95% CI) | 1.2 (0.2-9.3) | 4.1 (0.2-96) | 13.7 (0.7-260) |
| sTNFR1 | |||
| AUC | 0.60 | 0.67 | 0.88 |
| P | .26 | .21 | ≤.0001 |
| OR (95% CI) | 3.4 (0.4-30) | 8.3 (0.3-235) | 999+ (19-999+) |
| Best model by forward selection | IL6 | IL6, TIM3, sTNFR1 | ST2, sTNFR1 |
| AUC | .69 | .88 | .90 |
| P | .007 | .001 | <.0001 |
| OR (95% CI) | 3.2 (1.3-7.8) | 6.8 (1.3-35), 519 (3.6-999+), 0.0 (0.0-1.5), respectively | 17.2 (1.3-232), 999+ (13.3-1000+), respectively |
AUC, area under a ROC curve.